XSHE
002393
Market cap542mUSD
Jul 10, Last price
14.58CNY
1D
1.96%
1Q
-38.04%
Jan 2017
-64.70%
IPO
-74.33%
Name
Tianjin Lisheng Pharmaceutical Co Ltd
Chart & Performance
P/E
8.98
P/S
2.70
EPS
1.62
Div Yield, %
2.45%
Shrs. gr., 5y
0.24%
Rev. gr., 5y
4.99%
Revenues
1.39b
+4.23%
Net income
418m
+126.72%
CFO
452m
+411.94%
Dividend
Apr 29, 20250.35 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tianjin Lisheng Pharmaceutical Co.,Ltd. specializes in the manufacturing and distribution of chemical pharmaceutical products. Their extensive catalog features a variety of finished dosage forms, including tablets, hard capsules, dripping pills, freeze-dried powder injections, and water injections, alongside bulk medicines. The company also provides pharmaceutical intermediates, diagnostic reagents, biochemical reagents, and plastic bottles. Headquartered in Tianjin, China, the firm extends its reach through product exports. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2018‑00 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||